Treatment Decision-Making Framework and Emerging Bispecific Therapy Options

Dr. Nooka presents a case-based approach to treatment selection using a 50-year-old woman with relapsed/refractory multiple myeloma who progressed after 15 months on lenalidomide maintenance following quadruple induction therapy and autologous transplant. He outlines three critical decision-making factors: patient-related factors (logistical considerations, family obligations, job commitments), disease characteristics (high-risk cytogenetics, early progression behavior), and treatment-related characteristics (prior exposure to 4 drug classes including CD38 antibodies, PI, IMiD, and steroids with lenalidomide refractoriness).

Treatment options fall into three categories: CAR-T therapies, bispecific antibodies, and standard therapies. Although CAR-T represents optimal treatment for this high-risk patient, logistical barriers including three-month commitment at academic centers and lack of family support system make it impractical for many patients, with only approximately 20% of eligible patients proceeding with CAR-T.

Standard therapies include 18 NCCN category 1 recommendations, supported by randomized phase 3 trials demonstrating superiority. However, these trials primarily enrolled daratumumab-naïve patients, whereas current patients have CD38 antibody exposure. Despite this limitation, combinations like daratumumab-pomalidomide-dexamethasone remain effective with median progression-free survival of 15-18 months.

The paradigm-shifting MajesTEC-3 trial represents the third treatment bucket, comparing teclistamab (BCMA bispecific) plus daratumumab against standard daratumumab combinations. Results showed an unprecedented hazard ratio of 0.17 for progression-free survival, with 83% of patients remaining in remission at three years. This 83% reduction in progression/death risk, combined with unprecedented MRD negativity rates, positions teclistamab-daratumumab as a catalyst for bispecific adoption in early relapse settings for patients unable to receive CAR-T therapy.